# Anlotinib Versus Docetaxel as the Second-line Treatment in EGFR Wild Type Patients With Advanced NSCLC

> **NCT03703596** · PHASE2 · UNKNOWN · sponsor: **Sichuan Cancer Hospital and Research Institute** · enrollment: 88 (estimated)

## Conditions studied

- Lung Cancer
- Lung Cancer Metastatic

## Interventions

- **DRUG:** Anlotinib Hydrochloride
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT03703596
- **Lead sponsor:** Sichuan Cancer Hospital and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-10-16
- **Primary completion:** 2019-11-01
- **Final completion:** 2020-11-01
- **Target enrollment:** 88 (ESTIMATED)
- **Last updated:** 2018-10-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03703596

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03703596, "Anlotinib Versus Docetaxel as the Second-line Treatment in EGFR Wild Type Patients With Advanced NSCLC". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03703596. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*